Shanghai Securities News learned on February 24 that in order to curb the spread of the fifth round of the epidemic in Hong Kong, Guangdong Hybribio Biotech Co.Ltd(300639) deployed the first set of high-throughput screening laboratory from the mainland – Kaipu “triumph” negative pressure hard gas membrane laboratory to Hong Kong to help prevent and control the epidemic, including more than 100 nucleic acid extractors, amplifiers and a large number of testing equipment, consumables and materials to rush to Hong Kong, And reserve two sets of gas film laboratories ready for reinforcement at any time. The negative pressure hard film laboratory completed the test last weekend and officially opened on February 23.
According to the introduction of the company, Guangdong Hybribio Biotech Co.Ltd(300639) deputy general manager Guan Zhisheng has personally presided over Hong Kong since January, integrated the team strength of Hong Kong and the mainland, and established the Hong Kong combat command. Since the outbreak to February this year, Guangdong Hybribio Biotech Co.Ltd(300639) covid-19 nucleic acid has detected more than 80 million people. Guangdong Hybribio Biotech Co.Ltd(300639) its Kemp Hong Kong molecular pathology center (hkmpdc) has detected more than 6 million people. At present, Guangdong Hybribio Biotech Co.Ltd(300639) undertakes more than one-third of the testing tasks designated by the HKSAR government.
After the fifth round of epidemic in Hong Kong, Guangdong Hybribio Biotech Co.Ltd(300639) management quickly formed the anti epidemic headquarters and urgently dispatched more than 120 Kaipu anti epidemic elites from all over the country to Hong Kong. Dr. Huang Libao of Kaipu Hong Kong molecular pathology testing center and Dr. Zeng Cuiying, a clinical laboratory scientist, also led a team to join the Hong Kong battle command. Kaipu Hong Kong Laboratory and the “triumph” gas film laboratory mode were linked to achieve a maximum detection capacity of 110000 tubes in a single day.
